In conclusion, this study is the first meta-analysis to systematically review the clinical efficacy and therapeutic safety of PD-1 inhibitors in patients with advanced ESCC in second-line setting. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.